Key clinical point: Compared with topical corticosteroids (TCS) alone, lebrikizumab+TCS significantly improved outcomes in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: At week 16, a significantly higher proportion of patients in the lebrikizumab+TCS vs placebo+TCS group achieved an Investigator’s Global Assessment score of 0 or 1 (41.2% vs 22.1%; P = .01) and a 75% improvement in the Eczema Area and Severity Index (69.5% vs 42.2%; P < .001). The frequencies of patient-reported serious adverse events (AE) were similar in both groups (<2%); most treatment-emergent AE were of mild or moderate severity.
Study details: Findings are from a multicenter phase 3 study, ADhere, including 211 patients aged ≥ 12 years with moderate-to-severe AD who were randomly assigned to receive lebrikizumab+TCS (n = 145) or placebo+TCS (n = 66).
Disclosures: This study was sponsored by Dermira, Inc; a wholly-owned subsidiary of Eli Lilly and Company. Some authors reported ties with various organizations, including Eli Lilly. Six authors declared being employees or stockholders of Eli Lilly.
Source: Simpson EL et al for the ADhere Investigators. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: A randomized clinical trial (ADhere). JAMA Dermatol. 2023 (Jan 11). Doi: 10.1001/jamadermatol.2022.5534